Serveur d'exploration sur la maladie de Parkinson

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Microdialysis study of the effects of the antiparkinsonian drug budipine on L‐DOPA‐induced release of dopamine and 5‐hydroxytryptamine by rat substantia nigra and corpus striatum

Identifieur interne : 001D65 ( Main/Exploration ); précédent : 001D64; suivant : 001D66

Microdialysis study of the effects of the antiparkinsonian drug budipine on L‐DOPA‐induced release of dopamine and 5‐hydroxytryptamine by rat substantia nigra and corpus striatum

Auteurs : C. S. Biggs [Royaume-Uni] ; M. S. Starr [Royaume-Uni]

Source :

RBID : ISTEX:231C126A1611B15CF7C10381604CC7BD0C1CA831

English descriptors

Abstract

The purpose of this study was to determine if systemic treatment with the antiparkinsonian drug budipine was capable of influencing the release of dopamine newly synthesised from L‐DOPA in the substantia nigra and corpus striatum of the monoamine‐depleted rat. Dual probe microdialysis was therefore employed in freely moving animals pretreated with reserpine (4 mg/kg i.p. 18–20 h earlier) and α‐methyl‐p‐tyrosine (200 mg/kg i.p. 45 min earlier). Budipine (10 mg/kg i.p.) alone evoked a small but significant increase in basal dopamine efflux in nigra, though not in striatum, but did not affect the spontaneous outputs of DOPAC, 5‐HT, or 5‐HIAA in either structure. A threshold amount of L‐DOPA (25 mg/kg i.p.) stimulated the release of dopamine, DOPAC, and 5‐HT (but not 5‐HIAA), both in nigra and striatum. The L‐DOPA‐induced releases of dopamine and DOPAC were greatly accentuated by pretreatment with budipine (10 mg/kg i.p. 45 min earlier), which delayed rather than potentiated the nigral and striatal effluxes of 5‐HT. A higher dose of L‐DOPA (100 mg/kg i.p.) did not significantly raise the outputs of dopamine or 5‐HT, but greatly magnified that of DOPAC. In these experiments, pretreatment with budipine (10 mg/kg i.p.) facilitated the formation of DOPAC from L‐DOPA, without increasing the extracellular concentration of dopamine. We conclude from these findings that budipine, at a therapeutically relevant dose, potentiates the release of dopamine newly synthesised from L‐DOPA from either end of the nigrostriatal dopamine axis. This effect of budipine could be related to the drug's recently described ability to increase the activity of the converting enzyme, aromatic L‐amino acid decarboxylase, and could explain the clinical efficacy of budipine as an adjunct to L‐DOPA therapy of Parkinson's disease in man. The significance of 5‐HT release to the antiparkinsonian L‐DOPA, and the delay in this release caused by budipine, remain to be established. Synapse 34:36–46, 1999. © 1999 Wiley‐Liss, Inc.

Url:
DOI: 10.1002/(SICI)1098-2396(199910)34:1<36::AID-SYN5>3.0.CO;2-G


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Microdialysis study of the effects of the antiparkinsonian drug budipine on L‐DOPA‐induced release of dopamine and 5‐hydroxytryptamine by rat substantia nigra and corpus striatum</title>
<author>
<name sortKey="Biggs, C S" sort="Biggs, C S" uniqKey="Biggs C" first="C. S." last="Biggs">C. S. Biggs</name>
</author>
<author>
<name sortKey="Starr, M S" sort="Starr, M S" uniqKey="Starr M" first="M. S." last="Starr">M. S. Starr</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:231C126A1611B15CF7C10381604CC7BD0C1CA831</idno>
<date when="1999" year="1999">1999</date>
<idno type="doi">10.1002/(SICI)1098-2396(199910)34:1<36::AID-SYN5>3.0.CO;2-G</idno>
<idno type="url">https://api.istex.fr/document/231C126A1611B15CF7C10381604CC7BD0C1CA831/fulltext/pdf</idno>
<idno type="wicri:Area/Main/Corpus">000908</idno>
<idno type="wicri:Area/Main/Curation">000791</idno>
<idno type="wicri:Area/Main/Exploration">001D65</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Microdialysis study of the effects of the antiparkinsonian drug budipine on L‐DOPA‐induced release of dopamine and 5‐hydroxytryptamine by rat substantia nigra and corpus striatum</title>
<author>
<name sortKey="Biggs, C S" sort="Biggs, C S" uniqKey="Biggs C" first="C. S." last="Biggs">C. S. Biggs</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Pharmacology, The School of Pharmacy, London</wicri:regionArea>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Starr, M S" sort="Starr, M S" uniqKey="Starr M" first="M. S." last="Starr">M. S. Starr</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Pharmacology, The School of Pharmacy, London</wicri:regionArea>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Synapse</title>
<title level="j" type="abbrev">Synapse</title>
<idno type="ISSN">0887-4476</idno>
<idno type="eISSN">1098-2396</idno>
<imprint>
<publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="1999-10">1999-10</date>
<biblScope unit="volume">34</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="36">36</biblScope>
<biblScope unit="page" to="46">46</biblScope>
</imprint>
<idno type="ISSN">0887-4476</idno>
</series>
<idno type="istex">231C126A1611B15CF7C10381604CC7BD0C1CA831</idno>
<idno type="DOI">10.1002/(SICI)1098-2396(199910)34:1<36::AID-SYN5>3.0.CO;2-G</idno>
<idno type="ArticleID">SYN5</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0887-4476</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>5‐hydroxytryptamine</term>
<term>budipine</term>
<term>corpus striatum</term>
<term>dopamine</term>
<term>microdialysis</term>
<term>reserpine</term>
<term>substantia nigra</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The purpose of this study was to determine if systemic treatment with the antiparkinsonian drug budipine was capable of influencing the release of dopamine newly synthesised from L‐DOPA in the substantia nigra and corpus striatum of the monoamine‐depleted rat. Dual probe microdialysis was therefore employed in freely moving animals pretreated with reserpine (4 mg/kg i.p. 18–20 h earlier) and α‐methyl‐p‐tyrosine (200 mg/kg i.p. 45 min earlier). Budipine (10 mg/kg i.p.) alone evoked a small but significant increase in basal dopamine efflux in nigra, though not in striatum, but did not affect the spontaneous outputs of DOPAC, 5‐HT, or 5‐HIAA in either structure. A threshold amount of L‐DOPA (25 mg/kg i.p.) stimulated the release of dopamine, DOPAC, and 5‐HT (but not 5‐HIAA), both in nigra and striatum. The L‐DOPA‐induced releases of dopamine and DOPAC were greatly accentuated by pretreatment with budipine (10 mg/kg i.p. 45 min earlier), which delayed rather than potentiated the nigral and striatal effluxes of 5‐HT. A higher dose of L‐DOPA (100 mg/kg i.p.) did not significantly raise the outputs of dopamine or 5‐HT, but greatly magnified that of DOPAC. In these experiments, pretreatment with budipine (10 mg/kg i.p.) facilitated the formation of DOPAC from L‐DOPA, without increasing the extracellular concentration of dopamine. We conclude from these findings that budipine, at a therapeutically relevant dose, potentiates the release of dopamine newly synthesised from L‐DOPA from either end of the nigrostriatal dopamine axis. This effect of budipine could be related to the drug's recently described ability to increase the activity of the converting enzyme, aromatic L‐amino acid decarboxylase, and could explain the clinical efficacy of budipine as an adjunct to L‐DOPA therapy of Parkinson's disease in man. The significance of 5‐HT release to the antiparkinsonian L‐DOPA, and the delay in this release caused by budipine, remain to be established. Synapse 34:36–46, 1999. © 1999 Wiley‐Liss, Inc.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Royaume-Uni</li>
</country>
<region>
<li>Angleterre</li>
<li>Grand Londres</li>
</region>
<settlement>
<li>Londres</li>
</settlement>
</list>
<tree>
<country name="Royaume-Uni">
<region name="Angleterre">
<name sortKey="Biggs, C S" sort="Biggs, C S" uniqKey="Biggs C" first="C. S." last="Biggs">C. S. Biggs</name>
</region>
<name sortKey="Starr, M S" sort="Starr, M S" uniqKey="Starr M" first="M. S." last="Starr">M. S. Starr</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D65 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001D65 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:231C126A1611B15CF7C10381604CC7BD0C1CA831
   |texte=   Microdialysis study of the effects of the antiparkinsonian drug budipine on L‐DOPA‐induced release of dopamine and 5‐hydroxytryptamine by rat substantia nigra and corpus striatum
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 18:06:51 2016. Site generation: Wed Mar 6 18:46:03 2024